Table 1. Characteristics of Documented Cases of 17 Systemic Allergic Reactions, 5 Allergic Reactions, and 3 Control Participants to mRNA COVID-19 Vaccines Administered at Stanford Hospital Between December 18, 2020, and January 26, 2021a.
Age, y | Sex | Race and ethnicity | History of allergies | History of anaphylaxis | Time to onset, min | Signs and symptoms during the initial reaction | Medications received | Code type | Skin test | Brighton level | Tryptase level, ng/mL | BAT | PEG IgE levels, ng/mL | PEG IgG levels, ng/mL | Time from first dose to blood draw, d |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Documented cases of systemic allergic reactions and allergic reactions | |||||||||||||||
20-29 | F | White, non-Hispanic | No | No | 10 | Nausea, tongue edema | Acetaminophen, dexamethasone, epinephrine, famotidine, loratadine | Emergency | NA | 2 | NA | NA | NA | NA | NA |
30-39b | F | Other, Hispanicc | Drug, food | Yes | 1 | Chest pain, fatigue, headache, heart palpitations | Diphenhydramine, epinephrine, fluticasone propionate | Outpatient | Negative to PEG, P80, and vaccine | 1 | NA | Positive to PEG and vaccine | <Cutoff | 679.9 | 38 |
50-59 | F | Black, non-Hispanic | No | No | 5 | Abdominal pain, dyspnea, hypotension, localized erythema, lightheadedness, presyncope, throat and chest tightness, tachycardia, airway swelling | Albuterol, diphenhydramine, epinephrine, famotidine, methylprednisolone | Emergency | Negative to PEG, P80, and vaccine | 1 | Baseline, 6; after reaction, 25 | Positive to PEG and vaccine | <Cutoff | <Cutoff | 35 |
40-49 | F | Asian, non-Hispanic | Drug, food, latex | Drug, food | 10 | Cough, cyanosis, generalized pruritus, localized urticaria, tachypnea | Albuterol, dexamethasone, diphenhydramine, epinephrine, famotidine, naloxone, ondansetron, potassium chloride | Emergency | Negative to PEG, P80, and vaccine | 2 | Baseline, 4; after reaction, 16 | Positive to PEG and vaccine | <Cutoff | 349.02 | 76 |
50-59 | F | Other, non-Hispanicc | Drug | Drug | 10 | Dizziness, shortness of breath, stridor | Dexamethasone, diphenhydramine, famotidine, lidocaine, magnesium sulfate, morphine, ondansetron, PEG, prednisone | Emergency | Negative to PEG, P80, and vaccine | 2 | Baseline, 3; after reaction, 20 | Positive to PEG and vaccine | <Cutoff | 805.02 | 44 |
20-29b | F | Native Hawaiian or other Pacific Islander, non-Hispanic | Drug, food | No | 30 | Generalized pruritus | Cetirizine, diphenhydramine | Outpatient | NA | Skin allergy | Baseline, 5; after reaction: 15 | NA | NA | NA | NA |
30-39 | M | Asian, non-Hispanic | No | No | 20 | Generalized rash, generalized pruritus | Fluocinonide, loratadine triamcinolone acetonide | Outpatient | NA | Skin allergy | NA | NA | NA | NA | NA |
30-39b | F | Other, non-Hispanicc | Drug | No | 5 | Dizziness, nausea, pharyngitis | Diphenhydramine, metoclopramide | Emergency | Negative to PEG, P80, and vaccine | 1 | NA | Positive to PEG and vaccine | <Cutoff | 6903.24 | 14 |
30-39 | F | White, non-Hispanic | Drug | No | 150 | Throat swelling, throat itching, localized angioedema; symptoms more intense following second dose; symptoms recurred at skin test | Diphenhydramine | Emergency | Negative to PEG and P80; positive to vaccine | 2 | Baseline, 6; after reaction, 19 | Positive to PEG and vaccine | <Cutoff | 1518.63 | 6 |
30-39 | F | Other, non-Hispanicc | Drug | No | 15 | Generalized erythema, face edema, ocular pruritus | Acetaminophen, diphenhydramine, epinephrine, famotidine, methylprednisolone | Emergency | NA | 3 | NA | NA | NA | NA | NA |
30-39 | F | Other, Hispanicc | No | No | 45 | Diaphoresis, generalized urticaria, lightheadedness, nausea | Diphenhydramine | Emergency | NA | 1 | Baseline, 2; after reaction, 16 | Positive to PEG and vaccine | <Cutoff | 1097.98 | 32 |
30-39 | F | Asian, non-Hispanic | No | No | 120 | Generalized erythema, generalized pruritus | Diphenhydramine, famotidine, hydrocortisone | Emergency | NA | Skin allergy | NA | NA | NA | NA | NA |
30-39 | F | White, non-Hispanic | Drug, food | No | 15 | Lightheadedness, localized erythema, localized urticaria, chest pain | Diphenhydramine, levothyroxine sodium | Emergency | NA | 1 | NA | NA | NA | NA | NA |
30-39 | F | Asian, non-Hispanic | Drug | No | 1 | Generalized pruritus, cough | None | Outpatient | Negative to PEG, P80, and vaccine | 2 | Baseline, 5; after reaction, 21 | Positive to PEG and vaccine | <Cutoff | 667.56 | 78 |
40-49 | F | White, non-Hispanic | Food | No | 15 | Shortness of breath, flushed, rash, difficulty breathing | Epinephrine, prednisone | Emergency | NA | 1 | Baseline, 3; after reaction, 14 | NA | NA | NA | NA |
40-49 | F | Other, non-Hispanicc | Environmental, food | No | 120 | Headache, localized urticaria, wheezing | Fexofenadine hydrochloride | Outpatient | Negative to PEG, P80, and vaccine | 1 | NA | Positive to PEG and vaccine | <Cutoff | 491.41 | 0 |
40-49 | M | Other, non-Hispanicc | No | No | 20 | Generalized erythema, generalized pruritus, generalized urticaria | NA | Emergency | NA | Skin allergy | NA | NA | NA | NA | NA |
40-49b | F | Asian, non-Hispanic | Food | No | 15 | Generalized pruritus, headache, heart palpitations | Diphenhydramine | Emergency | Negative to PEG, P80, and vaccine | 1 | NA | Positive to PEG and vaccine | <Cutoff | 2439.24 | 17 |
50-59b | F | White, non-Hispanic | Drug, food | Yes | 5 | Oral pruritus, localized erythema, throat tightness | Prednisone | Emergency | Negative to PEG, P80, and vaccine | 2 | NA | Positive to PEG and vaccine | <Cutoff | 679.07 | 57 |
50-59 | F | White, non-Hispanic | Drug | No | 2 | Dizziness, tachycardia, hypertension, cough | NA | Emergency | Negative to PEG, P80, and vaccine | 2 | NA | Negative to PEG; positive to vaccine | <Cutoff | 1518.63 | 68 |
50-59 | F | Other, non-Hispanicc | No | No | 90 | Hypertension, shortness of breath, palpitations | Ondansetron | Emergency | NA | 2 | NA | NA | NA | NA | NA |
50-59 | F | White, non-Hispanic | Drug, food | Drug, food | 10 | Oral pruritus, rash | Diphenhydramine, famotidine, methylprednisolone | Emergency | NA | Skin allergy | NA | NA | NA | NA | NA |
Control Participants | |||||||||||||||
50-59 | F | White, non-Hispanic | Drug | Drug | None | None | None | NA | Negative to PEG, P80, and vaccine | None | None | Negative to PEG and to vaccine | <Cutoff | <Cutoff | 0 |
50-59 | M | Hispanic | None | None | None | None | None | NA | Negative to PEG, P80, and vaccine | None | None | Negative to PEG and vaccine | <Cutoff | <Cutoff | 31 |
20-29b | F | Hispanic | Food | Food | None | None | None | NA | Negative to PEG, P80, and vaccine | None | None | Negative to PEG and vaccine | <Cutoff | <Cutoff | 67 |
Abbreviations: BAT, basophil activation testing; Ig, immunoglobulin; NA, not available; P80, polysorbate 80; PEG, polyethylene glycol.
Allergic reactions were defined as those symptoms that started within 3 hours of vaccination and included hives; swelling of mouth, lips, tongue, or throat; shortness of breath, wheezing, or chest tightness; or changes in blood pressure or loss of consciousness. Reactions were graded using Brighton criteria5 for those with systemic anaphylaxis. Tryptase was obtained at baseline in some individuals and within 2 hours for postreaction levels. Specific IgE and IgG to PEG were conducted among participants who consented for a blood draw. The blood draw was used for both the BAT and Ig assays from the same visit for the participant.
Individual received mRNA-1273 vaccine.
Races coded as other in the electronic medical record retained this categorization. No listed races or ethnicities were recoded as other for the purpose of this study.